Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H20O |
Molecular Weight | 156.2652 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCO)CCC=C(C)C
InChI
InChIKey=QMVPMAAFGQKVCJ-UHFFFAOYSA-N
InChI=1S/C10H20O/c1-9(2)5-4-6-10(3)7-8-11/h5,10-11H,4,6-8H2,1-3H3
Molecular Formula | C10H20O |
Molecular Weight | 156.2652 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Citronellol or beta-citronellol is a naturally occurring monoterpene compound prevalent in essential oils of various aromatic plant species, such as Cymbopogon citratus. This compound is considered FDA as safe (GRAS) for food use. Citronellol was studied as an analgesic compound in various pain models and its action was mediated by the inhibition of peripheral mediators as well as central inhibitory mechanisms that could be related to its strong antioxidant effect observed in vitro. Citronellol also was used to control T rubrum growth, a dermatophytic fungus. The anti-hyperalgesic effect of citronellol was also studied and was shown, that this effect was achieved through the spinal cord lamina I inhibition.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22350215 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22350215
in mice: it was investigated the antinociceptive and anti-inflammatory properties of citronellol (CT) in rodents. In mice, when evaluated against acetic-acid-induced abdominal writhing, CT (25, 50 and 100 mg/kg, i.p.) reduced (P < 0.001) the amount of writhing compared to the control group. In the formalin test, CT also significantly inhibited both the early (neurogenic pain) and the late (inflammatory pain) phases of formalin-induced licking (P < 0.001). When assessed in a thermal model of pain, CT (100 mg/kg, i.p.) caused a significant increase (P < 0.05) in the latency response on the hot-plate test.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28297637
The bioactivity of P. roseum essential oil and its three major compounds on larvae and egg rafts of Cx. pipiens was evaluated. The essential oil had a significant toxic effect on larvae and egg rafts of Cx. pipiens, with 50% lethal concentration (LC50) values of 5.49 and 0.45μg/mL, respectively. Major constituents, geraniol, citronellol and linalool resulted in LC50 values of 6.86, 7.64 and 14.87μg/mL on larvae, and 0.8, 0.67 and 1.27μg/mL on egg rafts. Essential oil and two of its constituents, citronellol and geraniol showed moderate knock-down on Cx. pipiens adults.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:57:58 GMT 2023
by
admin
on
Fri Dec 15 16:57:58 GMT 2023
|
Record UNII |
565OK72VNF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
DL-CITRONELLOL
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID3026726
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
6805
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
565OK72VNF
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
m3599
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
1424650
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
8779
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
8842
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
203-375-0
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
SUB128631
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
106-22-9
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY | |||
|
565OK72VNF
Created by
admin on Fri Dec 15 16:57:58 GMT 2023 , Edited by admin on Fri Dec 15 16:57:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (GC)
|